Investigating how a specific protein affects lung cancer development
The role of translation initiation factor eIF5B in lung cancer pathogenesis
This study is looking at how a specific protein called eIF5B affects another protein, PD-L1, in lung cancer cells, which helps tumors hide from the immune system, and it hopes to find new ways to improve treatment for patients with non-small cell lung cancer who aren't responding to current therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ut Southwestern Medical Center NIH-funded |
| Lab location | 1 site (Dallas, United States) |
| Project ID | NIH-10883646 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of the translation initiation factor eIF5B in lung cancer, particularly how it influences the expression of PD-L1, a protein that helps tumors evade the immune system. By using advanced CRISPR-based screening techniques, the study aims to identify the mechanisms that regulate PD-L1 levels in lung cancer cells. The findings could reveal new therapeutic targets for improving treatment outcomes in patients with non-small cell lung cancer, especially those who do not respond to existing immunotherapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with non-small cell lung cancer, particularly those who have not responded to current immunotherapy treatments.
Not a fit: Patients with lung cancer who have already benefited from existing immunotherapies or those with other types of cancer may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that enhance the effectiveness of immunotherapy for lung cancer patients.
How similar studies have performed: Previous research has shown promising results in targeting immune checkpoints in cancer, suggesting that this approach could lead to significant advancements in treatment.
Where this research is happening
Dallas, United States
- Ut Southwestern Medical Center — Dallas, United States (Active)
Researchers
- Principal investigator: O'donnell, Kathryn Ann — Ut Southwestern Medical Center
- Study coordinator: O'donnell, Kathryn Ann
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.